GET DAILY SIGNALSEvommune (EVMN): Analyst Targets Point to +230% Upside From Current Levels
Key Takeaways
- The central $22 price target is the arithmetic mean of current analyst price targets, roughly $22 per share, based on about a dozen recent targets from Evommune, Inc. (EVMN).
- With the stock near $6.65, reaching $22 implies a rise of about 230% — a very large move.
- Current analyst targets range from a low of $8 to a high of $30, reflecting unusually wide disagreement after a sharp sell-off.
- Supporting factors include a large net cash position, a maturing inflammation-drug pipeline, and a majority "Buy" bias among analysts.
- The biggest risks are continued clinical and financial uncertainty, heavy share dilution, and a stock that trades far below its IPO price.
- For additional context, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- You can also discover AI-driven trade ideas by exploring Trending AI Robots.
Analyst Consensus on EVMN
Evommune, Inc. (EVMN) is a clinical-stage biotechnology company, not an exchange-traded fund. It develops therapies targeting drivers of chronic inflammatory diseases and went public in November 2025 at $16 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Roughly a dozen current analyst targets were reviewed. The most recent verifiable figures average near $22, with a wide range from a low of $8 to a high of $30. The arithmetic mean rounds to the $22 central target used here; independent aggregators report a mean of about $22.33 for the stock. That figure is a calculated average, not an official published consensus.
Views diverge sharply. Stifel Nicolaus maintained a Buy with a $30 target (November 5, 2026), while Morgan Stanley initiated coverage at $26 (October 20, 2026). Needham set $28 and Clear Street trimmed its target to $23, while Leerink Partners moved to $22 and RBC Capital to $21. On the cautious side, UBS initiated with a Hold and an $8 target, and H.C. Wainwright downgraded the shares to Neutral. Older targets of $50 to $55 were revised sharply lower as the stock declined and are not reflected in the current mean.
Where EVMN Stands Today and the Path to Target
The stock last traded near $6.65, down from a 52-week high of $33.20 and just above its 52-week low of $4.94. Reaching $22 would require an increase of about 230%, a very large move that would still leave the shares below their prior peak.
Fundamentally, Evommune is a pre-revenue drug developer. It holds roughly $200 million in cash against about $8.6 million in debt, a net cash position of around $5.29 per share, yet it burned more than $74 million in operating cash over the trailing twelve months and reported a net loss of about $95 million. Its Phase 2a atopic dermatitis data for its IL-18 pathway program underpinned the stock's early 2026 rally to $33, but the subsequent decline reflects investor re-pricing of development risk and dilution from a sharply higher share count. From what I see, the cash buffer stands out as a key differentiator versus many peers.
Factors That Could Support a Move Toward the Target
The central bull case rests on pipeline execution. Positive clinical readouts for its inflammation programs could meaningfully re-rate the shares, and the company's net cash provides a financial cushion. A majority of the most recent analyst actions remain Buy-rated, with targets far above the current price, and a strong cash balance reduces near-term financing risk relative to many peers. Renewed institutional interest in small-cap biotechnology or favorable sector sentiment could also help sentiment recover. I’m watching this closely for any shifts in biotech risk appetite.
Obstacles That Could Keep the Target Out of Reach
The obstacles are substantial. The stock trades well below both its IPO price and its book value per share of about $7.65, signaling deep skepticism. The share count has grown dramatically, dilution has been extreme, and the company posted an EPS (earnings per share) miss in its August 2026 report. Analysts remain split, with one major firm at just $8 and downgrades from H.C. Wainwright and William Blair's Hold rating underscoring caution. Additional capital raises, clinical setbacks, or a sustained risk-off environment in biotechnology could keep the stock anchored far below $22.
Technical Levels and Market Structure
Chart structure reflects the damage done by the sell-off. The $4.94 52-week low and the roughly $5.29 per-share net cash figure form a nearby support zone, while the 50-day moving average near $8 and the $8 UBS target mark initial resistance. Further overhead, the prior $10.47 low and the $16 IPO price are notable reference points, with the 200-day moving average near $17.45 well above current trading. Short interest near 10% of shares outstanding could amplify any rebound but also signals persistent bearish positioning.
Time Horizon and Key Items to Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch the company's next earnings release and clinical updates, guidance on cash runway and financing, analyst target revisions, and broader biotech risk appetite. Pipeline data events for the IL-18 program are the single most important catalyst for any move toward $22.
Final Assessment
The $22 central target is a calculated average of current analyst targets, not a guarantee, and it sits roughly 230% above the latest price. The strongest support comes from Evommune's cash cushion and the potential of its inflammation pipeline, while the principal obstacles are development risk, heavy dilution, and wide analyst disagreement spanning $8 to $30. With the stock near its lows and key clinical catalysts still ahead, the path to $22 is possible but requires a dramatic improvement in both data and sentiment. No outcome should be assumed, and investors should weigh the full range of targets rather than any single figure.
Using AI Tools to Track EVMN
For traders seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals offer a way to monitor shifting conditions without manually screening hundreds of names. The system uses artificial intelligence to continuously track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. This can help traders surface opportunities, monitor existing positions, and spot changing trends more efficiently — a useful complement to fundamental research on names like EVMN. In my view, it adds helpful context when evaluating names with wide analyst dispersion.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EVMN saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for EVMN moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 11 similar instances where the indicator exited the overbought zone. In 11 of the 11 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVMN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EVMN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EVMN's RSI Indicator exited the oversold zone, 6 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on EVMN as a result. In 16 of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for EVMN just turned positive on October 19, 2026. Looking at past instances where EVMN's MACD turned positive, the stock continued to rise in 5 of 6 cases over the following month. The odds of a continued upward trend are 83%.
Following a +10.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVMN advanced for three days, in 33 of 41 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (3.498). P/E Ratio (-0.562) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (34.014) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. EVMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement